Arginine and nitric oxide synthase: Regulatory mechanisms and cardiovascular aspects

Molecular Nutrition and Food Research

Volumn 58, Issue 1, 2014, Pages 101-116

  Lorin, Julie ^a   Zeller, Marianne ^a   Guilland, Jean Claude ^a   Cottin, Yves ^a   Vergely, Catherine ^a   Rochette, Luc ^a  

^a UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

Arginine; Cardiovascular; Nitric oxide synthase; Therapeutic potential

Indexed keywords

5,6,7,8-TETRAHYDROBIOPTERIN; ARGININE; BIOPTERIN; CITRULLINE; DRUG DERIVATIVE; NITRIC OXIDE SYNTHASE; TETRAHYDROBIOPTERIN;

ADIPOSE TISSUE; CARDIOVASCULAR; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; DIET; DIET SUPPLEMENTATION; HUMAN; METABOLISM; REVIEW; THERAPEUTIC EDUCATION; TRANSPORT AT THE CELLULAR LEVEL;

ARGININE; CARDIOVASCULAR; NITRIC OXIDE SYNTHASE; THERAPEUTIC POTENTIAL;

ADIPOSE TISSUE; ARGININE; BIOLOGICAL TRANSPORT; BIOPTERIN; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CITRULLINE; DIET; DIETARY SUPPLEMENTS; HUMANS; NITRIC OXIDE SYNTHASE;

EID: 84887987937     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201300033     Document Type: Review

References (151)

1. Baylis, C., Nitric oxide synthase derangements and hypertension in kidney disease. Curr. Opin. Nephrol. Hypertens, 2012, 21, 1-6.
2. Brunini, T. M., da Silva, C. D., Siqueira, M. A., Moss, M. B. et al., Uremia, atherothrombosis and malnutrition: the role of L-arginine-nitric oxide pathway. Cardiovasc. Hematol. Disord. Drug Targets 2006, 6, 133-140.
3. Li, P., Yin, Y. L., Li, D., Kim, S. W. et al., Amino acids and immune function. Br. J. Nutr. 2007, 98, 237-252.
4. Morris, S. M., Jr., Arginases and arginine deficiency syndromes. Curr. Opin. Clin. Nutr. Metabol. Care 2012, 15, 64-70.
5. Forstermann, U., Munzel, T., Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 2006, 113, 1708-1714.
6. Zeller, M., Korandji, C., Guilland, J. C., Sicard, P. et al., Impact of asymmetric dimethylarginine on mortality after acute myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 2008, 28, 954-960.
7. McKnight, J. R., Satterfield, M. C., Jobgen, W. S., Smith, S. B. et al., Beneficial effects of L-arginine on reducing obesity: potential mechanisms and important implications for human health. Amino Acids 2010, 39, 349-357.
8. Preli, R. B., Klein, K. P., Herrington, D. M., Vascular effects of dietary L-arginine supplementation. Atherosclerosis 2002, 162, 1-15.
9. Kim, J. H., Bugaj, L. J., Oh, Y. J., Bivalacqua, T. J. et al., Arginase inhibition restores NOS coupling and reverses endothelial dysfunction and vascular stiffness in old rats. J. Appl. Physiol. 2009, 107, 1249-1257.
10. White, A. R., Ryoo, S., Li, D., Champion, H. C. et al., Knockdown of arginase I restores NO signaling in the vasculature of old rats. Hypertension 2006, 47, 245-251.
11. Wu, G., Bazer, F. W., Davis, T. A., Kim, S. W. et al., Arginine metabolism and nutrition in growth, health and disease. Amino Acids 2009, 37, 153-168.
12. King, D. E., Mainous, A. G., 3rd, Geesey, M. E., Variation in L-arginine intake follow demographics and lifestyle factors that may impact cardiovascular disease risk. Nutr. Res. 2008, 28, 21-24.
13. Visek, W. J., Arginine needs, physiological state and usual diets. A reevaluation. J. Nutr. 1986, 116, 36-46.
14. Lassala, A., Bazer, F. W., Cudd, T. A., Datta, S. et al., Parenteral administration of L-arginine enhances fetal survival and growth in sheep carrying multiple fetuses. J. Nutr. 2011, 141, 849-855.
15. Li, X., Rezaei, R., Li, P., Wu, G., Composition of amino acids in feed ingredients for animal diets. Amino Acids 2011, 40, 1159-1168.
16. Salil, G., Nevin, K. G., Rajamohan, T., Arginine-rich coconut kernel diet influences nitric oxide synthase activity in alloxandiabetic rats. J. Sci. Food Agr. 2012, 92, 1903-1908.
17. Grimble, G. K., Adverse gastrointestinal effects of arginine and related amino acids. J. Nutr. 2007, 137, 1693S-1701S.
18. Wu, G., Bazer, F. W., Cudd, T. A., Jobgen, W. S. et al., Pharmacokinetics and safety of arginine supplementation in animals. J. Nutr. 2007, 137, 1673S-1680S.
19. Li, H., Meininger, C. J., Kelly, K. A., Hawker, J. R., Jr. et al., Activities of arginase I and II are limiting for endothelial cell proliferation. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2002, 282, R64-R69.
20. Morris, S. M., Jr., Recent advances in arginine metabolism: roles and regulation of the arginases. Br. J. Pharmacol. 2009, 157, 922-930.
21. Wu, G., Morris, S. M., Jr., Arginine metabolism: nitric oxide and beyond. Biochem. J. 1998, 336(Pt 1), 1-17.
22. Closs, E. I., Simon, A., Vekony, N., Rotmann, A., Plasma membrane transporters for arginine. J. Nutr. 2004, 134, 2752S-2759S; discussion 2765S-2767S.
23. Verrey, F., Closs, E. I., Wagner, C. A., Palacin, M. et al., CATs and HATs: the SLC7 family of amino acid transporters. Pflugers Arch. Eur. J. Physiol. 2004, 447, 532-542.
24. Arancibia-Garavilla, Y., Toledo, F., Casanello, P., Sobrevia, L., Nitric oxide synthesis requires activity of the cationic and neutral amino acid transport system y+L in human umbilical vein endothelium. Exp. Physiol. 2003, 88, 699-710.
25. Sobrevia, L., Gonzalez, M., A role for insulin on L-arginine transport in fetal endothelial dysfunction in hyperglycaemia. Curr. Vasc. Pharmacol. 2009, 7, 467-474.
26. Thomas, D. D., Ridnour, L. A., Isenberg, J. S., Flores-Santana, W. et al., The chemical biology of nitric oxide: implications in cellular signaling. Free Radic. Biol. Med. 2008, 45, 18-31.
27. Rousseau, D. L., Li, D., Couture, M., Yeh, S. R., Ligand-protein interactions in nitric oxide synthase. J. Inorg. Biochem. 2005, 99, 306-323.
28. Arnaud, C., Laubriet, A., Joyeux, M., Godin-Ribuot, D. et al., Role of nitric oxide synthases in the infarct size-reducing effect conferred by heat stress in isolated rat hearts. Br. J. Pharmacol. 2001, 132, 1845-1851.
29. Lecour, S., Maupoil, V., Siri, O., Tabard, A. et al., Electron spin resonance detection of nitric oxide generation in major organs from LPS-treated rats. J. Cardiovasc. Pharmacol. 1999, 33, 78-85.
30. Paya, D., Maupoil, V., Schott, C., Rochette, L. et al., Temporal relationships between levels of circulating NO derivatives, vascular NO production and hyporeactivity to noradrenaline induced by endotoxin in rats. Cardiovasc. Res. 1995, 30, 952-959.
31. Toda, N., Okamura, T., Modulation of renal blood flow and vascular tone by neuronal nitric oxide synthase-derived nitric oxide. J. Vasc. Res. 2011, 48, 1-10.
32. Daff, S., NO synthase: structures and mechanisms. Nitric Oxide 2010, 23, 1-11.
33. Zhang, Y. H., Casadei, B., Sub-cellular targeting of constitutive NOS in health and disease. J. Mol. Cell Cardiol. 2012, 52, 341-350.
34. Gielis, J. F., Lin, J. Y., Wingler, K., Van Schil, P. E. et al., Pathogenetic role of eNOS uncoupling in cardiopulmonary disorders. Free Radic. Biol. Med. 2011, 50, 765-776.
35. Roman, L. J., Masters, B. S., Electron transfer by neuronal nitric-oxide synthase is regulated by concerted interaction of calmodulin and two intrinsic regulatory elements. J. Biol. Chem. 2006, 281, 23111-23118.
36. Shimokawa, H., Tsutsui, M., Nitric oxide synthases in the pathogenesis of cardiovascular disease: lessons from genetically modified mice. Pflugers Arch. Eur. J. Physiol. 2010, 459, 959-967.
37. Carnicer, R., Crabtree, M. J., Sivakumaran, V., Casadei, B. et al., Nitric oxide synthases in heart failure. Antiox. Redox Signal. 2013, 18, 1078-1099.
38. Zhou, L., Zhu, D. Y., Neuronal nitric oxide synthase: structure, subcellular localization, regulation, and clinical implications. Nitric Oxide 2009, 20, 223-230.
39. Cauwels, A., Nitric oxide in shock. Kidney Int. 2007, 72, 557-565.
40. Crabtree, M. J., Channon, K. M., Synthesis and recycling of tetrahydrobiopterin in endothelial function and vascular disease. Nitric Oxide 2011, 25, 81-88.
41. Werner, E. R., Blau, N., Thony, B., Tetrahydrobiopterin: biochemistry and pathophysiology. Biochem. J. 2011, 438, 397-414.
42. Roe, N. D., Ren, J., Nitric oxide synthase uncoupling: a therapeutic target in cardiovascular diseases. Vascul. Pharmacol. 2012, 57, 168-172.
43. Zhang, L., Rao, F., Zhang, K., Khandrika, S. et al., Discovery of common human genetic variants of GTP cyclohydrolase 1 (GCH1) governing nitric oxide, autonomic activity, and cardiovascular risk. J. Clin.l Invest. 2007, 117, 2658-2671.
44. Gao, L., Chalupsky, K., Stefani, E., Cai, H., Mechanistic insights into folic acid-dependent vascular protection: dihydrofolate reductase (DHFR) mediated reduction in oxidant stress in endothelial cells and angiotensin II-infused mice: a novel HPLC-based fluorescent assay for DHFR activity. J. Mol. Cell Cardiol. 2009, 47, 752-760.
45. MacAllister, R. J., Parry, H., Kimoto, M., Ogawa, T. et al., Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br. J. Pharmacol. 1996, 119, 1533-1540.
46. Rees, D. D., Palmer, R. M., Schulz, R., Hodson, H. F. et al., Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br. J. Pharmacol. 1990, 101, 746-752.
47. Vallance, P., Leone, A., Calver, A., Collier, J. et al., Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992, 339, 572-575.
48. Bedford, M. T., Clarke, S. G., Protein arginine methylation in mammals: who, what, and why. Mol. Cell 2009, 33, 1-13.
49. Pope, A. J., Karuppiah, K., Cardounel, A. J., Role of the PRMT-DDAH-ADMA axis in the regulation of endothelial nitric oxide production. Pharmacol. Res. 2009, 60, 461-465.
50. Davids, M., van Hell, A. J., Visser, M., Nijveldt, R. J. et al., Role of the human erythrocyte in generation and storage of asymmetric dimethylarginine. Am J Physiol Heart Circ Physiol 2012, 302, H1762-1770.
51. Vallance, P., Leiper, J., Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. Arterioscler. Thromb. Vasc. Biol. 2004, 24, 1023-1030.
52. Valkonen, V. P., Paiva, H., Salonen, J. T., Lakka, T. A. et al., Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001, 358, 2127-2128.
53. Schwedhelm, E., Boger, R. H., The role of asymmetric and symmetric dimethylarginines in renal disease. Nat. Rev. Nephrol. 2011, 7, 275-285.
54. Cai, H., Harrison, D. G., Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res. 2000, 87, 840-844.
55. Feletou, M., Vanhoutte, P. M., Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). Am. J. Physiol. Heart Circ. Physiol. 2006, 291, H985-H1002.
56. Liu, V. W., Huang, P. L., Cardiovascular roles of nitric oxide: a review of insights from nitric oxide synthase gene disrupted mice. Cardiovasc. Res. 2008, 77, 19-29.
57. Kuhlencordt, P. J., Gyurko, R., Han, F., Scherrer-Crosbie, M. et al., Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice. Circulation 2001, 104, 448-454.
58. Ponnuswamy, P., Schrottle, A., Ostermeier, E., Gruner, S. et al., eNOS protects from atherosclerosis despite relevant superoxide production by the enzyme in apoE mice. PloS One 2012, 7, e30193.
59. Vergely, C., Perrin-Sarrado, C., Clermont, G., Rochette, L., Postischemic recovery and oxidative stress are independent of nitric-oxide synthases modulation in isolated rat heart. J. Pharmacol. Exp. Ther. 2002, 303, 149-157.
60. Padilla, F., Garcia-Dorado, D., Agullo, L., Inserte, J. et al., L-Arginine administration prevents reperfusion-induced cardiomyocyte hypercontracture and reduces infarct size in the pig. Cardiovasc. Res. 2000, 46, 412-420.
61. Mori, E., Haramaki, N., Ikeda, H., Imaizumi, T., Intra-coronary administration of L-arginine aggravates myocardial stunning through production of peroxynitrite in dogs. Cardiovasc. Res. 1998, 40, 113-123.
62. Pabla, R., Curtis, M. J., Nitric oxide fails to confer endogenous antiarrhythmic cardioprotection in the primate heart in vitro. Br. J. Pharmacol. 2007, 150, 893-898.
63. Colasanti, M., Suzuki, H., The dual personality of NO. Trends Pharmacol. Sci. 2000, 21, 249-252.
64. Ben Baouali, A., Aube, H., Maupoil, V., Blettery, B. et al., Plasma lipid peroxidation in critically ill patients: importance of mechanical ventilation. Free Radic. Biol. Med. 1994, 16, 223-227.
65. Lecour, S., Chevet, D., Maupoil, V., Moisant, M. et al., Intrarenal detection of nitric oxide using electron spin resonance spectroscopy in hypertensive lipopolysaccharide-treated rats. J. Cardiovasc. Pharmacol. 2002, 40, 9-17.
66. Medzhitov, R., Inflammation 2010: new adventures of an old flame. Cell 2010, 140, 771-776.
67. Andrades, M. E., Morina, A., Spasic, S., Spasojevic, I., Bench-to-bedside review: sepsis - from the redox point of view. Crit. Care 2011, 15, 230-242.
68. Vincent, J. L., Metabolic support in sepsis and multiple organ failure: more questions than answers. Crit. Care Med. 2007, 35, S436-S440.
69. Candipan, R. C., Wang, B. Y., Buitrago, R., Tsao, P. S. et al., Regression or progression. Dependency on vascular nitric oxide. Arterioscler. Thromb. Vasc. Biol. 1996, 16, 44-50.
70. Chin-Dusting, J. P., Willems, L., Kaye, D. M., L-arginine transporters in cardiovascular disease: a novel therapeutic target. Pharmacol. Ther. 2007, 116, 428-436.
71. Schulman, S. P., Becker, L. C., Kass, D. A., Champion, H. C. et al., L-arginine therapy in acute myocardial infarction: the vascular interaction with age in myocardial infarction (VINTAGE MI) randomized clinical trial. Jama 2006, 295, 58-64.
72. Tan, B., Li, X., Yin, Y., Wu, Z. et al., Regulatory roles for L-arginine in reducing white adipose tissue. Front. Biosci. 2012, 17, 2237-2246.
73. Alam, M. A., Kauter, K., Withers, K., Sernia, C. et al. Chronic L-arginine treatment improves metabolic, cardiovascular and liver complications in diet-induced obesity in rats. Food Func. 2013, 4, 83-91.
74. Carey Satterfield, M., Dunlap, K. A., Keisler, D. H., Bazer, F. W. et al., Arginine nutrition and fetal brown adipose tissue development in diet-induced obese sheep. Amino Acids 2012, 43, 1593-1603.
75. Jobgen, W., Meininger, C. J., Jobgen, S. C., Li, P. et al., Dietary L-arginine supplementation reduces white fat gain and enhances skeletal muscle and brown fat masses in diet-induced obese rats. J. Nutr. 2009, 139, 230-237.
76. Goette, A., Hammwohner, M., Bukowska, A., Scalera, F. et al., The impact of rapid atrial pacing on ADMA and endothelial NOS. Int. J. Cardiol. 2012, 154, 141-146.
77. Antoniades, C., Shirodaria, C., Leeson, P., Antonopoulos, A. et al., Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: implications for endothelial function in human atherosclerosis. Eur. Heart J. 2009, 30, 1142-1150.
78. Antoniades, C., Shirodaria, C., Warrick, N., Cai, S. et al., 5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation 2006, 114, 1193-1201.
79. Gomes, E., Duarte, R., Reis, R. P., Candido, A. et al., Homocysteine increase after acute myocardial infarction-can it explain the differences between case-control and cohort studies? Rev. Port. Cardiol. 2002, 21, 575-581.
80. Kim, H. L., Park, Y. S., Maintenance of cellular tetrahydrobiopterin homeostasis. BMB Rep. 2010, 43, 584-592.
81. Yan, J., Tie, G., Messina, L. M., Tetrahydrobiopterin, L-arginine and vitamin C act synergistically to decrease oxidative stress, increase nitricoxide and improve blood flow after induction of hindlimb ischemia in the rat. Mol. Med. 2012, 18, 676-684.
82. Antoniades, C., Shirodaria, C., Crabtree, M., Rinze, R. et al., Altered plasma versus vascular biopterins in human atherosclerosis reveal relationships between endothelial nitric oxide synthase coupling, endothelial function, and inflammation. Circulation 2007, 116, 2851-2859.
83. Antoniades, C., Cunnington, C., Antonopoulos, A., Neville, M. et al., Induction of vascular GTP-cyclohydrolase I and endogenous tetrahydrobiopterin synthesis protect against inflammation-induced endothelial dysfunction in human atherosclerosis. Circulation 2011, 124, 1860-1870.
84. Antoniades, C., Shirodaria, C., Van Assche, T., Cunnington, C. et al., GCH1 haplotype determines vascular and plasma biopterin availability in coronary artery disease effects on vascular superoxide production and endothelial function. J. Am. Coll. Cardiol. 2008, 52, 158-165.
85. Alp, N. J., Channon, K. M., Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. Arterioscler. Thromb. Vasc. Biol. 2004, 24, 413-420.
86. Heitzer, T., Krohn, K., Albers, S., Meinertz, T., Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with type II diabetes mellitus. Diabetologia 2000, 43, 1435-1438.
87. Crabtree, M. J., Smith, C. L., Lam, G., Goligorsky, M. S. et al., Ratio of 5, 6, 7, 8-tetrahydrobiopterin to 7, 8-dihydrobiopterin in endothelial cells determines glucose-elicited changes in NO vs. superoxide production by eNOS. Am. J. Physiol. Heart Circ. Physiol. 2008, 294, H1530-H1540.
88. Katusic, Z. S., d'Uscio, L. V., Nath, K. A., Vascular protection by tetrahydrobiopterin: progress and therapeutic prospects. Trends Pharmacol. Sci. 2009, 30, 48-54.
89. Hecker, M., Sessa, W. C., Harris, H. J., Anggard, E. E. et al., The metabolism of L-arginine and its significance for the biosynthesis of endothelium-derived relaxing factor: cultured endothelial cells recycle L-citrulline to L-arginine. Proc. Natl. Acad. Sci. USA 1990, 87, 8612-8616.
90. Schwedhelm, E., Maas, R., Freese, R., Jung, D. et al., Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: impact on nitric oxide metabolism. Br. J. Clin. Pharmacol. 2008, 65, 51-59.
91. Marquet-de Rouge, P., Clamagirand, C., Facchinetti, P., Rose, C. et al., Citrulline diet supplementation improves specific age-related raft changes in wild-type rodent hippocampus. Age (Dordr) 2012, DOI: 10.1007/s11357-012-9462-2
92. Jiang, L., Fang, J., Moore, D. S., Gogichaeva, N. V. et al., Age-associated changes in synaptic lipid raft proteins revealed by two-dimensional fluorescence difference gel electrophoresis. Neurobiol. Aging 2010, 31, 2146-2159.
93. Ananthakrishnan, M., Barr, F. E., Summar, M. L., Smith, H. A. et al., L-citrulline ameliorates chronic hypoxia-induced pulmonary hypertension in newborn piglets. Am. J. Physiol. 2009, 297, L506-L511.
94. El-Kirsh, A. A., Abd El-Wahab, H. M., Abd-Ellah Sayed, H. F., The effect of L-arginine or L-citrulline supplementation on biochemical parameters and the vascular aortic wall in high-fat and high-cholesterol-fed rats. Cell Biochem. Funct. 2011, 29, 414-428.
95. Hayashi, T., Juliet, P. A., Matsui-Hirai, H., Miyazaki, A. et al., L-citrulline and L-arginine supplementation retards the progression of high-cholesterol-diet-induced atherosclerosis in rabbits. Proc. Natl. Acad. Sci. USA 2005, 102, 13681-13686.
96. Kleinbongard, P., Schulz, R., Rassaf, T., Lauer, T. et al., Red blood cells express a functional endothelial nitric oxide synthase. Blood 2006, 107, 2943-2951.
97. Deves, R., Boyd, C. A., Transporters for cationic amino acids in animal cells: discovery, structure, and function. Physiol. Rev. 1998, 78, 487-545.
98. Mendes Ribeiro, A. C., Hanssen, H., Kiessling, K., Roberts, N. B. et al., Transport of L-arginine and the nitric oxide inhibitor NG-monomethyl-L-arginine in human erythrocytes in chronic renal failure. Clin. Sci. Lond. 1997, 93, 57-64.
99. Procter, L. D., Meier, C. F., Hamilton, C., Gerughty, A. R. et al., y+ cationic amino acid transport of arginine in packed red blood cells. J. Surg. Res. 2013, 179, e183-e187.
100. Shima, Y., Maeda, T., Aizawa, S., Tsuboi, I. et al., L-arginine import via cationic amino acid transporter CAT1 is essential for both differentiation and proliferation of erythrocytes. Blood 2006, 107, 1352-1356.
101. Omodeo-Sale, F., Cortelezzi, L., Vommaro, Z., Scaccabarozzi, D. et al., Dysregulation of L-arginine metabolism and bioavailability associated to free plasma heme. Am. J. Physiol. Cell Physiol. 2010, 299, C148-C154.
102. Ozuyaman, B., Grau, M., Kelm, M., Merx, M. W. et al., RBC NOS: regulatory mechanisms and therapeutic aspects. Trends Mol. Med. 2008, 14, 314-322.
103. Ulker, P., Yaras, N., Yalcin, O., Celik-Ozenci, C. et al., Shear stress activation of nitric oxide synthase and increased nitric oxide levels in human red blood cells. Nitric Oxide 2011, 24, 184-191.
104. Vergely, C., Maupoil, V., Clermont, G., Bril, A. et al., Identification and quantification of free radicals during myocardial ischemia and reperfusion using electron paramagnetic resonance spectroscopy. Arch. Biochem. Biophys. 2003, 420, 209-216.
105. Giustarini, D., Milzani, A., Colombo, R., Dalle-Donne, I. et al., Nitric oxide, S-nitrosothiols and hemoglobin: is methodology the key? Trends Pharmacol. Sci. 2004, 25, 311-316.
106. Balakumar, P., Kathuria, S., Taneja, G., Kalra, S. et al., Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins? J. Mol. Cell Cardiol. 2012, 52, 83-92.
107. Sicard, P., Delemasure, S., Korandji, C., Segueira-Le Grand, A. et al., Anti-hypertensive effects of Rosuvastatin are associated with decreased inflammation and oxidative stress markers in hypertensive rats. Free Radic. Res. 2008, 42, 226-236.
108. Bor-Kucukatay, M., Yalcin, O., Gokalp, O., Kipmen-Korgun, D. et al., Red blood cell rheological alterations in hypertension induced by chronic inhibition of nitric oxide synthesis in rats. Clin. Hemorheol. Microcir. 2000, 22, 267-275.
109. Uyuklu, M., Meiselman, H. J., Baskurt, O. K., Role of hemoglobin oxygenation in the modulation of red blood cell mechanical properties by nitric oxide. Nitric Oxide 2009, 21, 20-26.
110. Bogdan, C., Nitric oxide and the immune response. Nat. Immunol. 2001, 2, 907-916.
111. Popovic, P. J., Zeh, H. J., 3rd, Ochoa, J. B., Arginine and immunity. J. Nutr. 2007, 137, 1681S-1686S.
112. Yeramian, A., Martin, L., Serrat, N., Arpa, L. et al., Arginine transport via cationic amino acid transporter 2 plays a critical regulatory role in classical or alternative activation of macrophages. J. Immunol. 2006, 176, 5918-5924.
113. Schutz, T., Valentini, L., Herbst, B., Lochs, H., [ESPEN guidelines on enteral nutrition-summary]. Z. Gastroenterol. 2006, 44, 683-684.
114. Chase, S. D., Magnani, J. L., Simon, S. I., E-selectin ligands as mechanosensitive receptors on neutrophils in health and disease. Ann. Biomed. Eng. 2012, 40, 849-859.
115. He, P., Leucocyte/endothelium interactions and microvessel permeability: coupled or uncoupled? Cardiovasc. Res. 2010, 87, 281-290.
116. Wong, C. H., Heit, B., Kubes, P., Molecular regulators of leucocyte chemotaxis during inflammation. Cardiovasc. Res. 2010, 86, 183-191.
117. Gorsuch, W. B., Chrysanthou, E., Schwaeble, W. J., Stahl, G. L., The complement system in ischemia-reperfusion injuries. Immunobiology 2012, 217, 1026-1033.
118. Park, J. L., Lucchesi, B. R., Mechanisms of myocardial reperfusion injury. Ann. Thorac. Surg. 1999, 68, 1905-1912.
119. Sicard, P., Oudot, A., Guilland, J. C., Moreau, D. et al., Dissociation between vascular oxidative stress and cardiovascular function in Wistar Kyoto and spontaneously hypertensive rats. Vascul. Pharmacol. 2006, 45, 112-121.
120. Clermont, G., Vergely, C., Jazayeri, S., Lahet, J. J. et al., Systemic free radical activation is a major event involved in myocardial oxidative stress related to cardiopulmonary bypass. Anesthesiology 2002, 96, 80-87.
121. Goudeau, J. J., Clermont, G., Guillery, O., Lemaire-Ewing, S. et al., In high-risk patients, combination of antiinflammatory procedures during cardiopulmonary bypass can reduce incidences of inflammation and oxidative stress. J. Cardiovasc. Pharmacol. 2007, 49, 39-45.
122. Arora, T. K., Malhotra, A. K., Ivatury, R., Mangino, M. J., L-arginine infusion during resuscitation for hemorrhagic shock: impact and mechanism. J. Trauma Acute Care Surg. 2012, 72, 397-402.
123. Wang, X., Liang, F., Jiao, X., Liu, L. et al., Diverse effects of L-arginine on cardiac function of rats subjected to myocardial ischemia and reperfusion in vivo. Acta Biochim. Biophys. Sin. 2007, 39, 201-207.
124. Liang, F., Gao, E., Tao, L., Liu, H. et al., Critical timing of L-arginine treatment in post-ischemic myocardial apoptosis-role of NOS isoforms. Cardiovasc. Res. 2004, 62, 568-577.
125. Brunner, F., Leonhard, B., Kukovetz, W. R., Mayer, B., Role of endothelin, nitric oxide and L-arginine release in ischaemia/reperfusion injury of rat heart. Cardiovasc. Res. 1997, 36, 60-66.
126. Mizuno, T., Watanabe, M., Sakamoto, T., Sunamori, M., L-arginine, a nitric oxide precursor, attenuates ischemia-reperfusion injury by inhibiting inositol-1, 4, 5-triphosphate. J. Thorac. Cardiovasc. Surg. 1998, 115, 931-936.
127. Vergely, C., Perrin-Sarrado, C., Clermont, G., Rochette, L., Postischemic recovery and oxidative stress are independent of nitric oxide synthases modulation in isolated rat heart. J. Pharmacol. Exp. Therap. 2002, 303, 149-157.
128. Adams, M. R., Jessup, W., Celermajer, D. S., Cigarette smoking is associated with increased human monocyte adhesion to endothelial cells: reversibility with oral L-arginine but not vitamin C. J. Am. Coll. Cardiol. 1997, 29, 491-497.
129. Campisi, R., Czernin, J., Schoder, H., Sayre, J. W. et al., L-Arginine normalizes coronary vasomotion in long-term smokers. Circulation 1999, 99, 491-497.
130. Siasos, G., Tousoulis, D., Vlachopoulos, C., Antoniades, C. et al., Short-term treatment with L-arginine prevents the smoking-induced impairment of endothelial function and vascular elastic properties in young individuals. Int. J. Cardiol. 2008, 126, 394-399.
131. Campbell, K. A., Lipinski, M. J., Doran, A. C., Skaflen, M. D. et al., Lymphocytes and the adventitial immune response in atherosclerosis. Circ. Res. 2012, 110, 889-900.
132. Taube, A., Schlich, R., Sell, H., Eckardt, K. et al., Inflammation and metabolic dysfunction: links to cardiovascular diseases. Am. J. Physiol. Heart Circ. Physiol. 2012, 302, H2148-H2165.
133. Gao, Y. J., Takemori, K., Su, L. Y., An, W. S. et al., Perivascular adipose tissue promotes vasoconstriction: the role of superoxide anion. Cardiovasc. Res. 2006, 71, 363-373.
134. Gao, Y. J., Lu, C., Su, L. Y., Sharma, A. M. et al., Modulation of vascular function by perivascular adipose tissue: the role of endothelium and hydrogen peroxide. Br. J. Pharmacol. 2007, 151, 323-331.
135. Marchesi, C., Ebrahimian, T., Angulo, O., Paradis, P. et al., Endothelial nitric oxide synthase uncoupling and perivascular adipose oxidative stress and inflammation contribute to vascular dysfunction in a rodent model of metabolic syndrome. Hypertension 2009, 54, 1384-1392.
136. Meijer, R. I., Bakker, W., Alta, C. L., Sipkema, P. et al., Perivascular adipose tissue control of insulin-induced vasoreactivity in muscle is impaired in db/db mice. Diabetes 2013, 62, 590-598.
137. Mehebik, N., Jaubert, A. M., Sabourault, D., Giudicelli, Y. et al., Leptin-induced nitric oxide production in white adipocytes is mediated through PKA and MAP kinase activation. Am. J. Physiol. Cell Physiol. 2005, 289, C379-C387.
138. Niang, F., Benelli, C., Ribiere, C., Collinet, M. et al., Leptin induces nitric oxide-mediated inhibition of lipolysis and glyceroneogenesis in rat white adipose tissue. J. Nutr. 2011, 141, 4-9.
139. Spoto, B., Parlongo, R. M., Parlongo, G., Sgro, E. et al., The enzymatic machinery for ADMA synthesis and degradation is fully expressed in human adipocytes. J. Nephrol. 2007, 20, 554-559.
140. Gary, J. D., Clarke, S., RNA and protein interactions modulated by protein arginine methylation. Prog. Nucleic Acid Res. Mol. Biol. 1998, 61, 65-131.
141. Csanyi, G., Taylor, W. R., Pagano, P. J., NOX and inflammation in the vascular adventitia. Free Radic. Biol. Med. 2009, 47, 1254-1266.
142. Wisse, B. E., The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J. Am. Soc. Nephrol. 2004, 15, 2792-2800.
143. Jobgen, W., Fu, W. J., Gao, H., Li, P. et al., High fat feeding and dietary L-arginine supplementation differentially regulate gene expression in rat white adipose tissue. Amino Acids 2009, 37, 187-198.
144. Fu, W. J., Haynes, T. E., Kohli, R., Hu, J. et al., Dietary L-arginine supplementation reduces fat mass in Zucker diabetic fatty rats. J. Nutr. 2005, 135, 714-721.
145. Wu, G., Collins, J. K., Perkins-Veazie, P., Siddiq, M. et al., Dietary supplementation with watermelon pomace juice enhances arginine availability and ameliorates the metabolic syndrome in Zucker diabetic fatty rats. J. Nutr. 2007, 137, 2680-2685.
146. Wu, Z., Satterfield, M. C., Bazer, F. W., Wu, G., Regulation of brown adipose tissue development and white fat reduction by L-arginine. Curr. Opin. Clin. Nutr. Metabol. Care 2012, 15, 529-538.
147. Chen, J., Kuhlencordt, P., Urano, F., Ichinose, H. et al., Effects of chronic treatment with L-arginine on atherosclerosis in apoE knockout and apoE/inducible NO synthase double-knockout mice. Arterioscler. Thromb. Vasc. Biol. 2003, 23, 97-103.
148. Loscalzo, J., L-arginine and atherothrombosis. J. Nutr. 2004, 134, 2798S-2800S; discussion 2818S-2819S.
149. Ochiai, M., Hayashi, T., Morita, M., Ina, K. et al., Short-term effects of L-citrulline supplementation on arterial stiffness in middle-aged men. Int. J. Cardiol. 2012, 155, 257-261.
150. Orozco-Gutierrez, J. J., Castillo-Martinez, L., Orea-Tejeda, A., Vazquez-Diaz, O. et al., Effect of L-arginine or L-citrulline oral supplementation on blood pressure and right ventricular function in heart failure patients with preserved ejection fraction. Cardiol. J. 2010, 17, 612-618.
151. Moinard, C., Nicolis, I., Neveux, N., Darquy, S. et al., Dose-ranging effects of citrulline administration on plasma amino acids and hormonal patterns in healthy subjects: the citrudose pharmacokinetic study. Br. J. Nutr. 2008, 99, 855-862.